Frank Hazevoets
Chief Executive Officer at DMS IMAGING
Frank Hazevoets active positions
| Companies | Position | Start | End |
|---|---|---|---|
| DMS IMAGING | Director/Board Member | 01/05/2019 | - |
| Chief Executive Officer | 12/10/2020 | - | |
| Director of Finance/CFO | 31/12/2019 | - | |
| Investor Relations Contact | 31/03/2019 | - |
Career history of Frank Hazevoets
Former positions of Frank Hazevoets
| Companies | Position | Start | End |
|---|---|---|---|
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Director of Finance/CFO | 30/04/2014 | 04/10/2018 |
| TIGENIX NV | Director of Finance/CFO | 31/12/2005 | 31/12/2011 |
| Corporate Secretary | 31/12/2005 | 31/12/2011 | |
| InBev SA | Corporate Officer/Principal | 31/12/2000 | 31/12/2005 |
| Smeets Securities BV | Corporate Officer/Principal | - | - |
| Puilaetco | Corporate Officer/Principal | - | - |
Training of Frank Hazevoets
| Université Catholique de Louvain | Graduate Degree |
Statistics
International
| Belgium | 7 |
| 2 |
Operational
| Director of Finance/CFO | 3 |
| Corporate Officer/Principal | 3 |
| Corporate Secretary | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DMS IMAGING | Health Technology |
| Private companies | 5 |
|---|---|
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
| Puilaetco | Finance |
| Smeets Securities BV | |
| InBev SA | Consumer Non-Durables |
- Stock Market
- Insiders
- Frank Hazevoets
- Experience
